4 days ago
PTGX
AnalystsEtzer DaroutEtzer Darout's Stock Forecasts
AnalystsEtzer Darout
Sectors:
Analyst Ranking
Top 2%
#68 out of 5325 analysts
Average Return
+39.79%
Win Rate
63%117 out of 187
Risk vs Reward
Poor
Good
Etzer Darout's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Terns Pharmaceuticals IncTERN | +1,725.86% | $2.90 | $52.95 | 2025-05-13 - 2026-05-04 | Buy |
Five Prime Therapeutics IncFPRX | +884.42% | $3.85 | $37.90 | 2020-09-22 - 2021-03-09 | Strong Buy |
Terns Pharmaceuticals IncTERN | +614.59% | $7.40 | $52.88 | 2025-09-17 - 2026-03-30 | Strong Buy |
Terns Pharmaceuticals IncTERN | +549.63% | $8.14 | $52.88 | 2025-10-22 - 2026-03-30 | Strong Buy |
Scholar Rock Holding CorpSRRK | +278.17% | $8.45 | $31.96 | 2024-08-09 - 2025-08-08 | Buy |
Etzer Darout Analyst Color
Get additional color on Etzer Darout's coverage of popular stocks
4 days ago
JAZZ
2 months ago
JAZZ
2 months ago
RLAY
2 months ago
ARVN
2 months ago
ANAB
2 months ago
JAZZ
3 months ago
ORKA
3 months ago
MGNX
3 months ago
JAZZ
3 months ago
CLDX
3 months ago
RLAY
3 months ago
ORKA
4 months ago
ABVX
4 months ago
PTGX
4 months ago
CTMX
4 months ago
ORKA
4 months ago
SRRK
4 months ago
ANAB
5 months ago
CCCC
5 months ago
XNCR
5 months ago
IOVA
5 months ago
CTMX
6 months ago
CRVS
6 months ago
CTMX
Etzer Darout's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Protagonist Therapeutics IncPTGX | 8 | Strong Buy | $151.00 | +14.38% | Maintains | 4 days ago |
Jazz Pharmaceuticals PLCJAZZ | 5 | Strong Buy | $260.00 | +7.36% | Maintains | 4 days ago |
Incyte CorpINCY | 4 | Strong Buy | $134.00 | +14.87% | Maintains | 4 days ago |
Exelixis IncEXEL | 8 | Hold | $49.00 | -12.00% | Maintains | 4 days ago |
Nuvalent IncNUVL | 7 | Hold | $124.00 | +0.03% | Downgrades | a month ago |
Relay Therapeutics IncRLAY | 2 | Strong Buy | $27.00 | +39.39% | Maintains | 2 months ago |
Arvinas IncARVN | 8 | Strong Buy | $20.00 | +149.07% | Maintains | 2 months ago |
Anaptysbio IncANAB | 7 | Strong Buy | $75.00 | +38.50% | Maintains | 2 months ago |
Scholar Rock Holding CorpSRRK | 11 | Strong Buy | $55.00 | +6.32% | Maintains | 2 months ago |
Celldex Therapeutics IncCLDX | 5 | Strong Buy | $48.00 | +35.59% | Maintains | 2 months ago |
Syndax Pharmaceuticals IncSNDX | 2 | Strong Buy | $37.00 | +62.92% | Maintains | 3 months ago |
Oruka Therapeutics IncORKA | 4 | Strong Buy | $160.00 | +92.68% | Maintains | 3 months ago |
First Tracks Biotherapeutics IncTRAX | 1 | Strong Buy | $40.00 | +10.47% | Initiates Coverage On | 3 months ago |
Macrogenics IncMGNX | 11 | Strong Buy | $6.00 | +45.63% | Maintains | 3 months ago |
Tvardi Therapeutics IncTVRD | 3 | Strong Sell | $3.00 | -2.60% | Downgrades | 3 months ago |
Janux Therapeutics IncJANX | 4 | Strong Sell | $14.00 | -11.62% | Downgrades | 3 months ago |
Terns Pharmaceuticals IncTERN | 12 | Hold | $53.00 | +0.09% | Downgrades | 4 months ago |
Abivax SaABVX | 2 | Strong Buy | $148.00 | +7.43% | Maintains | 4 months ago |
Cytomx Therapeutics IncCTMX | 13 | Strong Buy | $16.00 | +336.56% | Maintains | 4 months ago |
Biontech SeBNTX | 5 | Buy | $128.00 | +39.80% | Maintains | 4 months ago |
C4 Therapeutics IncCCCC | 7 | Strong Buy | $7.00 | +95.53% | Maintains | 5 months ago |
Xencor IncXNCR | 9 | Strong Buy | $27.00 | +80.60% | Maintains | 5 months ago |
Vir Biotechnology IncVIR | 1 | Strong Buy | $30.00 | +219.15% | Maintains | 5 months ago |
Iovance Biotherapeutics IncIOVA | 3 | Strong Buy | $11.00 | +136.05% | Maintains | 5 months ago |
Rapt Therapeutics IncRAPT | 4 | Hold | $58.00 | -0.03% | Downgrades | 6 months ago |
Corvus Pharmaceuticals IncCRVS | 2 | Strong Buy | $28.00 | +96.22% | Maintains | 6 months ago |
Summit Therapeutics IncSMMT | 3 | Hold | $18.00 | +30.81% | Upgrades | 7 months ago |
Kymera Therapeutics IncKYMR | 4 | Strong Buy | $119.00 | +4.40% | Maintains | 7 months ago |
Kura Oncology IncKURA | 1 | Strong Buy | $28.00 | +157.12% | Maintains | 8 months ago |
Monopar TherapeuticsMNPR | 1 | Strong Buy | $125.00 | +15.19% | Initiates Coverage On | 9 months ago |
Merus NvMRUS | 8 | Hold | $97.00 | +7.78% | Downgrades | 10 months ago |
Inventiva SaIVA | 4 | Strong Buy | $13.00 | +187.61% | Maintains | a year ago |
Verve Therapeutics IncVERV | 1 | Strong Buy | $24.00 | N/A | Maintains | a year ago |
Q32 Bio IncQTTB | 3 | Hold | $3.00 | N/A | Downgrades | a year ago |
Igm Biosciences IncIGMS | 2 | Hold | $2.00 | N/A | Downgrades | 2 years ago |
Tourmaline Bio IncTRML | 1 | Buy | $50.00 | N/A | Initiates Coverage On | 2 years ago |
Nurix Therapeutics IncNRIX | 1 | Buy | $35.00 | N/A | Initiates Coverage On | 2 years ago |
Jasper Therapeutics IncJSPR | 1 | Buy | $63.00 | N/A | Initiates Coverage On | 2 years ago |
Acrivon Therapeutics IncACRV | 7 | Buy | $27.00 | N/A | Maintains | 2 years ago |
Genmab AGMAB | 3 | Buy | $48.00 | N/A | Reiterates | 2 years ago |
Novartis AgNVS | 3 | Hold | $120.00 | N/A | Maintains | 2 years ago |
Y Mabs Therapeutics IncYMAB | 5 | Buy | $25.00 | N/A | Maintains | 2 years ago |
Fate Therapeutics IncFATE | 7 | Hold | $6.00 | N/A | Maintains | 2 years ago |
Astrazeneca PLCAZN | 4 | Buy | $82.00 | N/A | Maintains | 2 years ago |
Immunogen IncIMGN | 4 | Hold | $31.00 | N/A | Downgrades | 3 years ago |
Foghorn Therapeutics IncFHTX | 2 | Buy | $19.00 | N/A | Maintains | 3 years ago |
Seagen IncSGEN | 4 | Hold | $229.00 | N/A | Downgrades | 3 years ago |
Alnylam Pharmaceuticals IncALNY | 2 | Strong Buy | $170.00 | N/A | Upgrades | 4 years ago |
Traws Pharma IncTRAW | 1 | Strong Buy | $60.00 | N/A | Initiates Coverage On | 5 years ago |
Five Prime Therapeutics IncFPRX | 2 | Hold | $38.00 | N/A | Downgrades | 5 years ago |
Akero Therapeutics IncAKRO | 1 | Strong Buy | $54.00 | N/A | Initiates Coverage On | 5 years ago |
Eidos Therapeutics IncEIDX | 2 | Hold | N/A | N/A | Downgrades | 6 years ago |
Mirum Pharmaceuticals IncMIRM | 1 | Strong Buy | $38.00 | N/A | Maintains | 6 years ago |
Aclaris Therapeutics IncACRS | 1 | Buy | $52.00 | N/A | Maintains | 8 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.